C-Rad AB (publ) (CRAD_B) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to our Q4 presentation. We close the year with growing order intake and solid profitability. But let me first zoom out briefly and take you through C-RED's long-term strategy and our progress for Q4 and 2024. As most of you already know, C-RED is active within radiation therapy, and more than half of all cancer patients undergo radiation therapy at some point of their treatment. So let me take you through this slide from left to right. First, we have a market-leading, patient-centric portfolio integrated with all leading LENAC, Proton, and CT suppliers. And I'm proud that we have over 1,900 systems supplied globally. Secondly, we have a global reach and are expanding -by-step. And in the fourth quarter, we have successfully broadened our base of installations in APAC, and that is visible in the 112% revenue growth in Q4. Thirdly, C-RED sees an untapped potential in both advanced and developing markets, which we want to capture. And also for this quarter, we had U.S. retrofit wins on Varian Linux. In fact, more than half of the orders are intended for Varian Linux. And this is a good step in the right direction to strengthen our position in the U.S. market, and that is a priority for us. And finally, C-RED has good financial stability, and we continue to display a solid profitability also in Q4. So let's go into a few takeaways for Q4 and the full year. The year ended with a recovered order intake of 168 million SEC, a 13% growth compared to Q4 last year. The main contribution came from EMEA, but also from Americas. And our focus on services paid off in the quarter. The full year was impacted by macroeconomic challenges, and the order intake was down by 7% to 486 million SEC. This was softened, however, by an improved fourth quarter. The order backlog increase...